BRIEF—Destiny Pharma CEO leaves abruptly

Brighton, UK-based infectious disease specialist Destiny Pharma has announced the resignation of chief executive Neil Clark, with immediate effect.

Current non-executive director Debra Barker will fill in while a permanent replacement is found. Destiny said Mr Clark would also continue to “support the business for a limited period, to ensure an orderly handover.”

Destiny recently secured  an exclusive collaboration and co-development agreement for its lead candidate NTCD-M3 with Sebela Pharmaceuticals.

The company launched as a publicly-traded entity on the AIM exchange in 2017.